• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症的诊断:2017 年麦当劳标准的修订——连续性与变化。

Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.

机构信息

Department of Neurology, UKD and Center for Neurology and Neuropsychiatry, LVR Klinikum, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

Department of Neurology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

出版信息

Curr Opin Neurol. 2019 Jun;32(3):327-337. doi: 10.1097/WCO.0000000000000699.

DOI:10.1097/WCO.0000000000000699
PMID:30985371
Abstract

PURPOSE OF REVIEW

The purpose of this review is to describe the new 2017 revisions of the McDonald diagnostic criteria for multiple sclerosis and review first experiences in their application to different patient populations.

RECENT FINDINGS

The 2017 revisions agreed on by an international expert panel, as the precursors, define criteria needed to fulfill dissemination in time and space in the clinically isolated syndrome after exclusion of alternative diagnoses. One major change is the inclusion of cerebrospinal fluid (CSF) oligoclonal bands as evidence of dissemination in time in a patient with dissemination in space gathered by clinical or magnetic resonance examination. The distinction between asymptomatic and symptomatic lesions in counting for evidence of dissemination in space or time in supra, infratentorial, and spinal cord syndrome has been abandoned. Finally, cortical lesions can be used to demonstrate dissemination in space. Major differential diagnoses, in particular, the still-evolving concept of neuromyelitis optica spectrum disorders and the myelin oligodendrocyte glycoprotein-IgG-related demyelinating central nervous system disorders.

SUMMARY

The new 2017 revisions will simplify the application of the MRI criteria for dissemination in space and include CSF findings as evidence for dissemination in time in clinically isolated syndrome.

摘要

目的综述

本次综述旨在描述多发性硬化症的新 2017 年修订版诊断标准,并回顾其在不同患者人群中应用的初步经验。

最新发现

国际专家组作为前身达成的 2017 年修订版,定义了在排除其他诊断后,临床孤立综合征中时间和空间传播所必需的标准。一个主要变化是将脑脊液(CSF)寡克隆带纳入时间传播的证据,以补充通过临床或磁共振检查收集的空间传播证据。在计算空间或时间传播的证据时,已不再区分无症状和有症状病变,用于上、下脑和脊髓综合征。最后,可以使用皮质病变来证明空间传播。主要鉴别诊断,特别是神经髓鞘炎视神经光谱障碍和髓鞘少突胶质细胞糖蛋白-IgG 相关脱髓鞘中枢神经系统障碍的概念仍在不断发展。

总结

新的 2017 年修订版将简化空间传播 MRI 标准的应用,并将 CSF 结果纳入临床孤立综合征中时间传播的证据。

相似文献

1
Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change.多发性硬化症的诊断:2017 年麦当劳标准的修订——连续性与变化。
Curr Opin Neurol. 2019 Jun;32(3):327-337. doi: 10.1097/WCO.0000000000000699.
2
[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].[多发性硬化症的诊断:2017年麦克唐纳标准修订版]
Nervenarzt. 2018 Dec;89(12):1344-1354. doi: 10.1007/s00115-018-0550-0.
3
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.多发性硬化症的诊断:2017 年麦当劳标准修订版。
Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
4
[Diagnosis of multiple sclerosis: A review of the 2017 revisions of the McDonald criteria].[多发性硬化症的诊断:2017年麦克唐纳标准修订版综述]
Ideggyogy Sz. 2018 Sep 30;71(9-10):321-329. doi: 10.18071/isz.71.0321.
5
Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.脑和脊髓病变标准将 AQP4 阳性视神经脊髓炎和 MO G 阳性疾病与多发性硬化症区分开来。
Mult Scler Relat Disord. 2018 Oct;25:246-250. doi: 10.1016/j.msard.2018.08.008. Epub 2018 Aug 9.
6
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.采用 2016 年 MAGNIMS 和 2010 年 McDonald 标准预测临床孤立综合征患者的多发性硬化症诊断:一项回顾性研究。
Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.
7
MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.MRI 和实验室特征及国际标准在儿童和青少年多发性硬化症诊断中的表现:一项前瞻性队列研究。
Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.
8
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.视神经脊髓炎及相关疾病中的髓鞘少突胶质细胞糖蛋白免疫球蛋白G:50例患者的多中心研究。第2部分:流行病学、临床表现、影像学和实验室特征、治疗反应及长期预后
J Neuroinflammation. 2016 Sep 27;13(1):280. doi: 10.1186/s12974-016-0718-0.
9
Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria.在克罗地亚临床孤立综合征患者中建立多发性硬化症的诊断:2010 年与 2017 年麦克唐纳标准的对比。
Mult Scler Relat Disord. 2018 Oct;25:99-103. doi: 10.1016/j.msard.2018.07.035. Epub 2018 Jul 20.
10
Diagnosis of multiple sclerosis: progress and challenges.多发性硬化症的诊断:进展与挑战。
Lancet. 2017 Apr 1;389(10076):1336-1346. doi: 10.1016/S0140-6736(16)30959-X. Epub 2016 Nov 24.

引用本文的文献

1
The Utility of Intravoxel Incoherent Motion Metrics in Assessing Disability in Relapsing-Remitting Multiple Sclerosis.体素内不相干运动指标在评估复发缓解型多发性硬化症残疾程度中的应用
Diagnostics (Basel). 2025 Aug 21;15(16):2113. doi: 10.3390/diagnostics15162113.
2
Building digital patient pathways for the management and treatment of multiple sclerosis.构建用于多发性硬化症管理和治疗的数字患者路径。
Front Immunol. 2024 Feb 15;15:1356436. doi: 10.3389/fimmu.2024.1356436. eCollection 2024.
3
Monitoring of the pharmacological treatment availability in patients with multiple sclerosis in the Greater Poland population.
大波兰地区多发性硬化症患者药物治疗可及性的监测。
Reumatologia. 2023;61(6):473-480. doi: 10.5114/reum/177143. Epub 2024 Jan 18.
4
Implementing coronavirus disease 2019 scale-up registry protocol in national multiple sclerosis registry system of Iran.在伊朗国家多发性硬化症登记系统中实施2019冠状病毒病扩大登记方案。
Curr J Neurol. 2021 Oct 7;20(4):241-245. doi: 10.18502/cjn.v20i4.8351.
5
Impaired intestinal permeability in patients with multiple sclerosis.多发性硬化症患者肠道通透性受损。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2025 Mar;169(1):37-43. doi: 10.5507/bp.2023.033. Epub 2023 Aug 11.
6
Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review.寡克隆带及其他脑脊液变量在多发性硬化症和其他神经免疫性疾病中的应用:一篇叙述性综述
Ann Transl Med. 2023 Apr 15;11(7):282. doi: 10.21037/atm-21-3073. Epub 2023 Jan 10.
7
[Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis].[复发缓解型多发性硬化症患者对富马酸二甲酯的实际依从性]
Rev Neurol. 2023 Jan 31;76(s01):S1-S6. doi: 10.33588/rn.76s01.2022296.
8
Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.中国 1990 年至 2019 年多发性硬化症负担和趋势:2019 年全球疾病负担研究的系统分析。
BMJ Open. 2022 Dec 8;12(12):e066335. doi: 10.1136/bmjopen-2022-066335.
9
Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).奥瑞珠单抗可降低复发型多发性硬化症(RMS)和进展型多发性硬化症(PMS)中的 TH40 细胞,TH40 细胞是全身性炎症的生物标志物。
J Neuroimmunol. 2023 Jan 15;374:578008. doi: 10.1016/j.jneuroim.2022.578008. Epub 2022 Dec 7.
10
Discovery of Novel Biomarkers for Diagnosing and Predicting the Progression of Multiple Sclerosis Using TMT-Based Quantitative Proteomics.采用 TMT 定量蛋白质组学发现用于诊断和预测多发性硬化症进展的新型生物标志物。
Front Immunol. 2021 Aug 20;12:700031. doi: 10.3389/fimmu.2021.700031. eCollection 2021.